58138-79-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2,6-DIIODOPYRAZINE is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals for its ability to contribute to the development of new and effective compounds.
Used in Organic Synthesis:
2,6-DIIODOPYRAZINE is used as a reagent in organic synthesis, specifically as a building block in the production of heterocyclic compounds, due to its unique chemical structure and properties.
Used in Material Science:
2,6-DIIODOPYRAZINE has been studied for its potential use in the development of new materials such as conducting polymers and electronic devices, owing to its possible applications in enhancing the performance of these materials.

InChI:InChI=1/C4H2I2N2/c5-3-1-7-2-4(6)8-3/h1-2H

Upstream product

• 4774-14-5 2,6-dichloropyrazine 

Downstream Products

• 58139-03-0 2-iodo-6-methoxypyrazine 
• 125060-66-4 2-iodo-6-(dimethylamino)pyrazine 
• 125060-75-5 2-iodo-6-allyloxypyrazine 
• 1009378-29-3 2-(6-iodo-pyrazin-2-yl)-4-methyl-thiazole-5-carboxylic acid benzylamide 

Relevant academic research and scientific papers

Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2

We report the discovery and structure-activity relationship of 2,6-disubstituted pyrazines, which are potent and selective CK2 inhibitors. Lead compound 1 was identified, and derivatives were prepared to develop potent inhibitory activity. As a result, we obtained compound 7, which was the smallest unit that retained potency. Then, introducing an aminoalkyl group at the 6-position of the indazole ring resulted in improved efficacy in both enzymatic and cell-based CK2 inhibition assays. Moreover, compound 13 showed selectivity against other kinases and in vivo efficacy in a rat nephritis model. These results show that 2,6-disubstituted pyrazines have potential as therapeutic agents for nephritis.

10-Step Asymmetric Total Synthesis and Stereochemical Elucidation of (+)-Dragmacidin D

The asymmetric synthesis of dragmacidin D (1) was completed in 10 steps. Its sole stereocenter was set by using direct asymmetric alkylation enabled by a C2-symmetric tetramine and lithium N-(trimethylsilyl)-tert-butylamide as the enolization r

tele-Substitution Reactions in the Synthesis of a Promising Class of 1,2,4-Triazolo[4,3- a]pyrazine-Based Antimalarials

We have discovered and studied a tele-substitution reaction in a biologically important heterocyclic ring system. Conditions that favor the tele-substitution pathway were identified: the use of increased equivalents of the nucleophile or decreased equivalents of base or the use of softer nucleophiles, less polar solvents, and larger halogens on the electrophile. Using results from X-ray crystallographic and isotope labeling experiments, a mechanism for this unusual transformation is proposed. We focused on this triazolopyrazine as it is the core structure of the in vivo active antiplasmodium compounds of Series 4 of the Open Source Malaria consortium.

Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases

Several five- and six-membered heterocycles were introduced to replace the C2-position amide bond of the original 2-aminothiazole-based hit compound 5. Specifically, replacement of the amide bond with an imidazolidinone moiety yielded a novel and potent thiazolylimidazolidinone series of SCD1 inhibitors. XEN723 (compound 22) was identified after optimization of the thiazolylimidazolidinone series. This compound demonstrated a 560-fold improvement in in vitro potency and reduced plasma desaturation indices in a dose dependent manner, with an EC50 of 4.5 mg/kg.

TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, co

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Identification and synthesis of volatiles released by the myxobacterium Chondromyces crocatus

Cultures of the myxobacterium Chondromyces crocatus on agar plates were analysed by closed-loop-stripping analysis or solid phase micro extraction. The odour profiles consist mainly of pyrazines, sesquiterpenoids and some aromatic compounds, summing up to more than 50 components. Several new pyrazines as 2-(1-hydroxy-1-methylethyl)-3-methoxypyrazine (9), 2-(1-hydroxy-1-methylpropyl)- 3-methoxypyrazine (10), and 2-(1-hydroxy-2-methylpropyl)-3-methoxypyrazine (11) were identified besides several known pyrazines. A major pyrazine occurring in most samples was 2,5-bis-(1-methylethyl)pyrazine (3). While the well known sesquiterpenoid geosmin (1) was present in low amounts, the related compound (1(10)E,5E)-germacradien-11-ol (21) was identified in most samples in larger quantities. Other prominent sesquiterpenoids not reported before from microorganisms were (6S,10S)-6,10-dimethylbicyclo[4.4.0]dec-1-en-3-one (16), which was accompanied by smaller amounts of several derivatives. The biosynthesis of these compounds is discussed in relation to the recently proposed biosynthetic pathways to 1 and 21.

A New Route to Arglecin by Metalation and Cross Coupling of Pyrazines. Metalation of Diazines. XII

The metalation of dihalogeno and halogenomethoxypyrazines was performed.The resulting pyrazines were submitted to a cross-coupling reaction with propargyl alcohol followed, after dehydration, by a catalytic reduction.This gives a new route to the synthesis of a key intermediate in the synthesis of arglecin.

Synthesis and muscarinic activity of quinuclidinyl- and (1- azanorbornyl)pyrazine derivatives

The synthesis and cortical muscarinic activity of a novel series of pyrazine-based agonists is described. Quinuclidine and azanorbornane derivatives were prepared either by reaction of lithiated pyrazines with azabicyclic ketones, followed by chlorination and reduction, or by reaction of the lithium enolate of the azabicyclic ester with 2-chloropyrazines followed by ester hydrolysis and decarboxylation. Substitution at all three positions of the heteroaromatic ring has been explored. Optimal muscarinic agonist activity was observed for unsubstituted pyrazines in the azanorbornane series. The exo-1-azanorbornane 18a is one of the most efficacious and potent centrally active muscarinic agonists known. Studies on the 3-substituted derivatives have provided evidence of the preferred conformation of these ligands for optimal muscarinic activity. Substitution at C6 gave ligands with increased affinity and reduced efficacy. Moving the position of the diazine ring nitrogens to give pyrimidine and pyridazine derivatives resulted in a significant loss of muscarinic activity.

Pyrazine compound useful as plant growth regulators

Pyrazine derivatives useful as plant growth regulating agents have the general formula: STR1 and stereoisomers thereof, wherein R1 is C1 -C4 alkyl optionally substituted with halogen, or cyclopropyl optionally substituted with C1 -C4 alkyl; R2 is C1 -C8 alkyl, C2 -C8 alkenyl, or C2 -C8 alkynyl each optionally substituted with halogen; C3 -C6 cycloalkyl, C3 -C6 cycloalkenyl, C3 -C6 cycloalkylalkyl, C3 -C6 cycloalkenylalkyl, phenylalkenyl or phenylalkynyl each optionally substituted on the ring group; R3 is hydrogen or C1 -C4 alkyl; R4 is hydrogen, C1 -C4 alkyl, halogen, alkylamino, cyano, or alkoxy; n is 0 or 1; and salts, ethers, acylates and metal complexes thereof.